摘要
慢性肾脏病(CKD)导致的肾性贫血是CKD患者常见并发症,可导致心血管并发症及死亡风险增高。目前主要的治疗方法为红细胞生成刺激剂(ESA)及铁剂联合治疗。但是国内目前临床上肾性贫血治疗达标率仍然较低。积极寻找ESA低反应原因并给予纠正,避免ESA及铁剂过量带来的相关不良反应须得到重视。新型治疗药物如低氧诱导因子-脯氨酰羟化酶抑制剂(HIF-PHI),为肾性贫血治疗带来新的时代。
Anemia is a common comorbidity in patients with chronic kidney disease(CKD).Erythropoiesis-stimulating agents(ESA)and iron therapy are still the predominantly therapies for most patients,although both have potential side effects.There still have a considerable ratio of patients with hemoglobin below the targets due to ESA low response.New strategies including HIF stabilizers are the promising agents for future therapies of renal anemia.
作者
程叙扬
赵明辉
CHENG Xu-yang;ZHAO Ming-hui(Department of Nephrology,First Hospital of Peking University and Institute of Nephrology,Peking University,Beijing 100034,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2020年第11期881-884,889,共5页
Chinese Journal of Practical Internal Medicine
